Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".